| pathology | Demonstrated benefit and harm | k | | | |
|---|
| cardiovascular prevention | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| picotamide vs placebo | | | | | picotamide vs placebo | | | | | picotamide vs placebo | | | | | Cocozza, 1995 | picotamide vs placebo | | | CV death 0.00 [0.00; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| ADEP, 1993 | Picotamide 600 mg / j (n=1150) vs. Placebo (n=1154) | patients with peripheral obstructive arterial disease (stade II+) | double blind Parallel groups Sample size: 1150/1154 Primary endpoint: Mortalité vasculaire et non vasculaire, IDM fatal ou non, AVC fatal ou non, amputation au dessus de FU duration: 18 months | | Neirotti, 1994 | Picotamide 900 mg / j (n=10) vs. Placebo (n=10) | patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months | double blind Parallel groups Sample size: 10/10 Primary endpoint: Paramètres hémodynamiques, de coagulation, d’activité plaquettaire FU duration: 18 months | | Coto, 1989 | Picotamide 900 mg / j (n=20) vs. Placebo (n=20) | patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètres de marche, paramètres sanguins FU duration: 6 months | | Cocozza, 1995 | picotamide 300 mg TID (n=25) vs. placebo (n=25) | normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (< 50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events | double blind Parallel groups Sample size: 25/25 Primary endpoint: not unique (carotid atherosclerotic lesions) FU duration: 24 months |
|
| diabetes type 2 | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Cocozza, 1995 | picotamide vs placebo | | | CV death 0.00 [0.00; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Cocozza, 1995 | picotamide 300 mg TID (n=25) vs. placebo (n=25) | normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (< 50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events | double blind Parallel groups Sample size: 25/25 Primary endpoint: not unique (carotid atherosclerotic lesions) FU duration: 24 months |
|
| peripheral vascular diseases | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| picotamide vs placebo | | | | | picotamide vs placebo | | | | | picotamide vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| ADEP, 1993 | Picotamide 600 mg / j (n=1150) vs. Placebo (n=1154) | patients with peripheral obstructive arterial disease (stade II+) | double blind Parallel groups Sample size: 1150/1154 Primary endpoint: Mortalité vasculaire et non vasculaire, IDM fatal ou non, AVC fatal ou non, amputation au dessus de FU duration: 18 months | | Neirotti, 1994 | Picotamide 900 mg / j (n=10) vs. Placebo (n=10) | patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months | double blind Parallel groups Sample size: 10/10 Primary endpoint: Paramètres hémodynamiques, de coagulation, d’activité plaquettaire FU duration: 18 months | | Coto, 1989 | Picotamide 900 mg / j (n=20) vs. Placebo (n=20) | patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètres de marche, paramètres sanguins FU duration: 6 months |
|
